XSWX:GALD (Switzerland)
Â
Registered Shares
CHF
78.55
+0.20 (+0.26%)
Apr 17
Warning! GuruFocus detected
1 Severe warning sign
with GALD.
Try a 7-Day Free Trial
to check it out.
What is a stock summary page? Click here for an overview.
Business Description
Galderma Group AG
ISIN : CH1335392721
Share Class Description:
XSWX:GALD: Registered SharesCompare
Compare
Traded in other countries / regions
GALD.SwitzerlandGALDz.UKGALDY.USAPY30.Germany IPO Date
2024-03-22Description
Galderma was formed in 1981 as a joint venture between Nestle and L'Oreal. It subsequently became a subsidiary of Nestle, called Nestle Skin Health, before being carved out and launched as a standalone company in 2019, acquired by a consortium led by Sweden-based EQT fund. The company went public in March 2024 and is listed on the SIX Swiss exchange. Galderma's science-based portfolio spans multiple dermatology categories, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. It derives around 45% of net sales from the US and employs around 6,600 people.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.17 | |||||
| Equity-to-Asset | 0.62 | |||||
| Debt-to-Equity | 0.35 | |||||
| Debt-to-EBITDA | 2.88 | |||||
| Interest Coverage | 1.9 | |||||
| Piotroski F-Score | N/A/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Future 3-5Y EPS without NRI Growth Rate Estimate | 63.06 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 11.9 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 41.76 | |||||
| 9-Day RSI | 36.11 | |||||
| 14-Day RSI | 34.64 | |||||
| 3-1 Month Momentum % | -15.46 | |||||
| 6-1 Month Momentum % | 15.39 | |||||
| 12-1 Month Momentum % | 45.83 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.21 | |||||
| Quick Ratio | 0.94 | |||||
| Cash Ratio | 0.3 | |||||
| Days Inventory | 109.9 | |||||
| Days Sales Outstanding | 62.52 | |||||
| Days Payable | 158.64 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward Dividend Yield % | 0.19 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 69.48 | |||||
| Operating Margin % | 15.27 | |||||
| Net Margin % | 5.2 | |||||
| FCF Margin % | 4.79 | |||||
| ROE % | 3.36 | |||||
| ROA % | 1.86 | |||||
| ROIC % | 4.4 | |||||
| ROC (Joel Greenblatt) % | 121.72 | |||||
| ROCE % | 6.1 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 90.7 | |||||
| Forward PE Ratio | 33.76 | |||||
| PE Ratio without NRI | 85.1 | |||||
| PS Ratio | 4.71 | |||||
| PB Ratio | 2.68 | |||||
| Price-to-Free-Cash-Flow | 98.56 | |||||
| Price-to-Operating-Cash-Flow | 42.92 | |||||
| EV-to-EBIT | 34.52 | |||||
| EV-to-Forward-EBIT | 29.97 | |||||
| EV-to-EBITDA | 23.97 | |||||
| EV-to-Forward-EBITDA | 21.78 | |||||
| EV-to-Revenue | 5.18 | |||||
| EV-to-Forward-Revenue | 4.76 | |||||
| EV-to-FCF | 108.12 | |||||
| Earnings Yield (Greenblatt) % | 2.9 | |||||
| FCF Yield % | 1.02 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Galderma Group AG Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil CHF) | 3,963.579 | ||
| EPS (TTM) (CHF) | 0.866 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 32.67 | ||
| 14-Day RSI | 34.64 | ||
| 14-Day ATR (CHF) | 4.270019 | ||
| 20-Day SMA (CHF) | 86.07 | ||
| 12-1 Month Momentum % | 45.83 | ||
| 52-Week Range (CHF) | 62.55 - 119.6 | ||
| Shares Outstanding (Mil) | 237.41 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Galderma Group AG Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Galderma Group AG Stock Events
| Event | Date | Price (CHF) | ||
|---|---|---|---|---|
| No Event Data | ||||
Galderma Group AG Frequently Asked Questions
What is Galderma Group AG(XSWX:GALD)'s stock price today?
The current price of XSWX:GALD is CHF78.55. The 52 week high of XSWX:GALD is CHF119.60 and 52 week low is CHF62.55.
When is next earnings date of Galderma Group AG(XSWX:GALD)?
The next earnings date of Galderma Group AG(XSWX:GALD) is 2025-07-24.
Does Galderma Group AG(XSWX:GALD) pay dividends? If so, how much?
Galderma Group AG(XSWX:GALD) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers